Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Taking Big Pharma’s R&D Argument Literally: Cut Prices, Or Increase Spending?

Executive Summary

Former Obama Administration official offers sophisticated and complicated approach to value-based pricing, tied back to drug development costs. The complexity alone makes the idea a non-starter for the current Administration, but it also begs the question of whether it would be more likely to cut costs – or just increase R&D spending?

You may also be interested in...



The Latest Furor Over Trump’s Drug Pricing Plan

Did the head of the Office and Management & Budget really endorse Part D rebates? Like so much about the Trump Administration’s response to drug pricing, there is probably a lot less to the story than it sounds.

Putting The 'Big' Back In PhRMA: New Membership Criteria Pares Ranks

PhRMA eliminates 42% of members in conjunction with new membership eligibility criteria stipulating minimum R&D investment levels.

“Frank” Talk On Drug Pricing: HHS Official Sees Value-Based Pricing As Area Of Common Interest

The most likely next step in executive branch action on drug pricing will be testing approaches to value-based pricing in categories where pharmaceutical companies are willing participants. That appears to be the message from an HHS official speaking at a DC policy event.

Topics

UsernamePublicRestriction

Register

PS120668

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel